Even in these grim times, deal makers have descended into silliness. Perhaps it is end-of-the-year exhaustion as we sputter toward the finish of a five-year market rally, but normally sober-minded business executives seem to have thrown over sound ...
Big Fees for Pfizer-Allergan Deal
Wall Street Journal (blog)
Political risk clouds Pfizer-Allergan deal
The Australian Financial Review